Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Vanda To Pay Eli Lilly Up To $100 Million In Drug Development Agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/16/2012 | 01:50pm CET

Vanda Pharmaceuticals Inc. (>> Vanda Pharmaceuticals Inc.) agreed to pay Eli Lilly Co. (LLY) up to $100 million for the exclusive right to develop a drug that has shown some promise as a treatment for alcohol addiction.

Under its deal with Lilly, the biopharmaceutical company will pay a $1 million initial license fee and take responsibility for all development costs of the VLY-686 drug.

Lilly is also eligible to receive additional payments based upon certain milestones and royalties on sales. These milestones include $4 million for milestones achieved prior to a new drug application and up to $95 million for future regulatory approval and sales milestones.

Vanda, which focuses on treatments for central nervous system disorders, noted that prior research of VLY-686 has focused on its potential as a novel therapeutic for individuals struggling with dependence on alcohol.

"The licensing of VLY-686 is an important milestone for Vanda, as we continue to realize our vision of developing treatments to address unmet medical needs," said Chief Executive Mihael H. Polymeropoulos.

Vanda in February reported it swung to a loss in the fourth quarter as increased expenses outweighed higher revenue for the period.

Shares closed Friday at $4.49 and were inactive in premarket trade. The stock has slumped 42% over the past year.

-By Mia Lamar, Dow Jones Newswires; 212-416-3207; [email protected]

Stocks mentioned in the article : Vanda Pharmaceuticals Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VANDA PHARMACEUTICALS INC.
12/01 VANDA PHARMACEUTICALS : New Vanda Pharmaceuticals’ Abstracts Suggest Circa..
11/15 VANDA PHARMACEUTICALS : Announces Participation at November 2017 Investor Confer..
11/13 VANDA PHARMACEUTICALS : Announces Participation at November 2017 Investor Confer..
11/10 VANDA PHARMACEUTICALS : Receives Negative Opinion for Marketing Authorization fr..
11/10 VANDA PHARMACEUTICALS : Receives Negative Opinion for Marketing Authorization fr..
11/08 VANDA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
11/07 VANDA PHARMACEUTICALS : reports 3Q loss
11/07 VANDA PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Fina..
11/07 VANDA PHARMACEUTICALS : Reports Third Quarter 2017 Financial Results
11/07 VANDA PHARMACEUTICALS INC. : to Host Earnings Call
More news
News from SeekingAlpha
11/10 Vanda strikes out in appeal of thumbs down from European advisory group on Fa..
11/07 Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q3 2017 Results - ..
11/07 Vanda Pharmaceuticals beats by $0.08, misses on revenue
11/06 Notable earnings after Tuesday?s close
10/31 BIOSCIENCE CATALYSTS : Global Blood Therapeutics And Vanda Pharmaceuticals
Financials ($)
Sales 2017 164 M
EBIT 2017 -22,3 M
Net income 2017 -16,2 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 3,93x
Capi. / Sales 2018 3,34x
Capitalization 645 M
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Technical analysis trends VANDA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 20,4 $
Spread / Average Target 42%
EPS Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Senior VP
Vincent J. Milano Independent Director
Michael F. Cola Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS INC.-10.03%645
GILEAD SCIENCES5.53%98 689
REGENERON PHARMACEUTICALS5.95%41 789
VERTEX PHARMACEUTICALS97.99%36 888
GENMAB-12.02%9 967
BLUEBIRD BIO INC196.52%8 385